Mustafa R. Bashir

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy et al. · The Lancet · 2019 · 733 citations

Metabolic Associated Steatohepatitis, Hepatology, Nonalcoholic Fatty Liver Disease +10

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Stephen A. Harrison, Mary E. Rinella, Manal F. Abdelmalek et al. · The Lancet · 2018 · 404 citations

Hepatology, Medicine, Liver Physiology +5

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Stephen A. Harrison, Rebecca Taub, Guy Neff et al. · Nature Medicine · 2023 · 348 citations · Full text

Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis

Michael S. Middleton, Elhamy Heba, Catherine A. Hooker et al. · Gastroenterology · 2017 · 262 citations · Full text

Metabolic Syndrome, Pathologist-assigned Steatosis Grades, Metabolic Associated Steatohepatitis +11

Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage

Mohammad Shadab Siddiqui, Goro Yamada, Raj Vuppalanchi et al. · Clinical Gastroenterology and Hepatology · 2019 · 258 citations · Full text

Fibrosis, Uterine Fibroids, Disease Progression +10